Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 3/2020

01-03-2020 | Prostate Cancer | Topic Paper

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

Authors: F. Kunath, P. J. Goebell, B. Wullich, D. Sikic, A. Kahlmeyer

Published in: World Journal of Urology | Issue 3/2020

Login to get access

Abstract

Purpose

Standard androgen deprivation therapy (ADT) can be initiated early at the time of diagnosis in asymptomatic castration-sensitive advanced prostate cancer. This definition has recently been expanded to also include an early combined treatment with standard ADT and new antihormonal drugs. We aimed to present the best available evidence for the timing of initiation of ADT monotherapy and combined treatments in castration-sensitive/-resistant prostate cancer.

Methods

For this narrative review, we searched Cochrane reviews in the Cochrane Library, systematic reviews and randomized controlled trials in MEDLINE, phase III and ongoing trials in ClinicalTrials.gov and screened the reference lists to extract articles of interest. One author screened the references which were finally included after assessing their relevance through discussion with other experts in the field.

Results

The identified references were grouped by medication (standard ADT, androgen biosynthesis inhibitor, androgen receptor antagonists or combined therapies) and tumor stage (castration sensitive or resistant). The evidence was narratively summarized and discussed in the context of the current therapeutic landscape.

Conclusions

Early standard ADT can reduce symptoms of disease progression and may extend progression-free and overall survival. The patient should be well informed about the higher rates of treatment-related side effects. Deferring standard ADT might be indicated only for well-informed or unfit patients. Early standard ADT is increasingly combined with new antihormonal drugs in castration-sensitive metastatic prostate cancer to gain additional survival and quality of life benefits. Combined treatment at the time of development of castration-resistant disease is well established.
Literature
1.
Antonarakis ES, Eisenberger MA (2009) Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nat Clin Pract Oncol 6(1):12–13PubMedCrossRef
2.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790PubMedPubMedCentralCrossRef
3.
Shore ND (2017) Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 18(9):945–952PubMedCrossRef
4.
5.
Hammerer PG, Wirth MP, Group EED-NL-s (2018) Health-related quality of life in 536 long-term prostate cancer survivors after treatment with leuprorelin acetate: a combined retrospective and prospective analysis. Urol Int 100(1):72–78PubMedCrossRef
6.
Kunath F, Keck B, Rucker G, Motschall E, Wullich B, Antes G et al (2013) Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review. BMC Cancer 13:131PubMedPubMedCentralCrossRef
7.
8.
9.
Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T et al (2017) Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 84:88–101PubMedPubMedCentralCrossRef
10.
Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW et al (2018) What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol 29(5):1249–1257PubMedPubMedCentralCrossRef
11.
Tan PS, Aguiar P Jr, Haaland B, Lopes G (2018) Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. Prostate Cancer Prost Dis 21:516–523CrossRef
12.
Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S et al (2018) Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur J Cancer 103:78–87PubMedCrossRef
13.
Kassem L, Shohdy KS, Abdel-Rahman O (2018) Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. Curr Med Res Opin 34(5):903–910PubMedCrossRef
14.
McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ (2018) The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and prostatic Dis 21(3):306–318CrossRef
15.
Xu L, Pachynski RK (2018) Contemporary management of the newly diagnosed prostate cancer patient with metastatic disease at presentation. Curr Urol Rep 19(10):79PubMedCrossRef
16.
17.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360PubMedCrossRef
18.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338–351PubMedPubMedCentralCrossRef
19.
20.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992PubMedCrossRef
21.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005PubMedPubMedCentralCrossRef
22.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148CrossRefPubMed
23.
Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, de Reijke TM (2017) First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials. BJU Int 119(6):831–845PubMedCrossRef
24.
Saeterdal I, Desser A, Pike E, Hamidi V, Harboe I, Odgaard-Jensen J et al (2016) Health technology assessment of four drugs for patients with metastatic castration resistant prostate cancer. NIPH Systematic Reviews. Oslo, Norway
25.
Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC et al (2017) Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget 8(48):84572–84578PubMedPubMedCentralCrossRef
26.
Wang Y, Zhang H, Shen W, He P, Zhou Z (2018) Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 144(9):1751–1768PubMedCrossRef
27.
Zhao Y, Huang H, Chen C, Liu H, Su F, Bi J et al (2018) Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. J Cancer 9(4):690–701PubMedPubMedCentralCrossRef
28.
Marchioni M, Sountoulides P, Bada M, Rapisarda S, De Nunzio C, Tamburro FR et al (2018) Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ‘real-life’ studies. Ther Adv Urol 10(10):305–315PubMedPubMedCentralCrossRef
29.
Tassinari D, Cherubini C, Roudnas B, Tamburini E, Drudi F, Bianchi E et al (2018) Treatment of metastatic, castration-resistant, docetaxel-resistant prostate cancer: a systematic review of literature with a network meta-analysis of randomized clinical trials. Rev Recent Clin Trials 13(3):226–237PubMedCrossRef
30.
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D et al (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17(2):153–163PubMedCrossRef
31.
Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M et al (2014) An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer Prost Dis 17(4):320–324CrossRef
32.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197PubMedCrossRef
33.
Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D et al (2014) Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 15(10):1147–1156PubMedCrossRef
34.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433PubMedPubMedCentralCrossRef
35.
Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S et al (2015) Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 16(5):509–521PubMedCrossRef
36.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 378(26):2465–2474PubMedPubMedCentralCrossRef
37.
Zheng H, Chen J, Qiu W, Lin S, Chen Y, Liang G, et al. (2017) Safety and efficacy of first-line treatments for chemotherapy-naive metastatic castration-resistant prostate cancer: a systematic review and indirect comparison. BioMed Res Int ID3941217:10
38.
Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, de Reijke TM (2017) Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: a systematic review of nine randomized controlled trials. Semin Oncol 44(5):358–371PubMedCrossRef
39.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408–1418PubMedCrossRef
40.
Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S et al (2018) Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 19:1404–1414PubMedCrossRef
41.
Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL et al (2016) Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol 69(5):834–840PubMedCrossRef
42.
Fizazi K, Albiges L, Loriot Y, Massard C (2015) ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther 15(9):1007–1017PubMedPubMedCentralCrossRef
43.
44.
45.
46.
47.
Tucci M, Leone G, Buttigliero C, Zichi C, Di Stefano RF, Pignataro D et al (2018) Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva Urol Nefrol 70(2):144–151PubMed
48.
Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863PubMedCrossRef
49.
Kunath F, Borgmann H, Blumle A, Keck B, Wullich B, Schmucker C et al (2015) Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer. a systematic review with meta-analysis. BMJ Open 5(11):e008217PubMedPubMedCentralCrossRef
50.
Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F et al (2016) Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70(2):256–262CrossRefPubMed
51.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158PubMedCrossRef
52.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746PubMedPubMedCentralCrossRef
53.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177PubMedPubMedCentralCrossRef
54.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080–1087PubMedPubMedCentralCrossRef
Metadata
Title
Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review
Authors
F. Kunath
P. J. Goebell
B. Wullich
D. Sikic
A. Kahlmeyer
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 3/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02704-y

Other articles of this Issue 3/2020

World Journal of Urology 3/2020 Go to the issue

Original Article

Minimally invasive robotic versus conventional open living donor kidney transplantation

Topic Paper

Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?

Original Article

Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy?

Original Article

Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations

Correction

Correction to: Evidence-based approach to active surveillance of prostate cancer

Original Article

Thermal effects of Ho:YAG laser lithotripsy during retrograde intrarenal surgery and percutaneous nephrolithotomy in an ex vivo porcine kidney model